

# Vyhledávání, rešerše a další informačně-knihovnické služby v oblastech competitive intelligence

*Richard Papík*


- *Ústav bohemistiky a knihovnictví FPF Slezské univerzity*
- *Ústřední knihovna Univerzity Karlovy*

<http://www.linkedin.com/in/papik>

<http://www.facebook.com/richard.papik>

***Searching Session 2016***

Akce konaná v úterý 4.10. 2016 v Národní technické knihovně v Praze, venku  
nádherně deštivo, což je přímo ideální pro seminář nebo četbu ...



?

**Co je competitive intelligence a co  
možná není, a také co zásadně  
není...**

REALLY NOT A SIMPLE ANSWER

# WHAT'S THE "Oj"?

(also Bi, Mi)?

STRATEGY: FINANCIAL... ANALYSIS ?  
MANAGER'S GAME ?

(WAR)  
btw: COMPETITIVE GAMES  
(~ GAME THEORY)



TODAY'S LECTURE

THEORY ON SES

② CORPORATE COMBAT  
② ETHIC  
② INFORMATION WORK / LIBRARIANSHIP

TEAM WORK ?


DIPLOMACY ?

CORPORATE INTELLIGENCE AND ESPIONAGE (INDUSTRIAL) ?

SIMILARITY WITH MILITARY (INTELLIGENCE) ?

"SYNONYMS" (SOMETIMES)

- COMPETITIVE 1.
- COMPETITOR 1.
- COMPANY 1.
- CORPORATE 1.
- MARKET 1.
- BUSINESS 1.



# ... důsledky pro profesi

## Profese:

- ◆ Competitive Intelligence Professional
- ◆ Chief Information Officer
- ◆ Chief Knowledge Officer
- ◆ Research and Information Specialist
- ◆ Research Analyst
- ◆ Knowledge Analyst
- ◆ ale také Science Librarian, information officer ph.

## Vztah ke knihovnicko-informační praxi:

- ◆ *<http://www.sla.org>, <http://www.ala.org>*
- ◆ *<http://www.aiip.org>,*
- ◆ *<http://www.scip.org>*

# Kategorizace a výběrově příklady

- ◆ HUMINT
- ◆ GEOINT
- ◆ MASINT
- ◆ FININT
- ◆ TECHINT
- ◆ ...
- ◆ **OSINT**




# Typologie a vhodnost KI služeb, zkoumání informačního chování uživatelské skupiny






# Umístění informačního brokeringu k informačnímu průmyslu

## Tři základní subjekty informačního průmyslu



Jsou knihovny a jim podobné instituce vhodné pro služby uživatelům se vztahem k CI? ... **jsou a jak** 😊





# **Komentování případových úloh ...**

## Mapping the Indian nanotechnology innovation system

### Article Options and Tools

View:  HTML |  PDF

[References \(16\)](#)

[Add to Marked List](#) | [Download Citation](#) | [Track Citations](#) | [Reprints & Permissions](#)

**Author(s):** Amit Kumar (Centre for Studies in Science Policy, Jawaharlal Nehru University, New Delhi, India)  
Pranav N. Desai (Centre for Studies in Science Policy, Jawaharlal Nehru University, New Delhi, India)

**Citation:** Amit Kumar , Pranav N. Desai , (2014) "Mapping the Indian nanotechnology innovation system", World Journal of Science, Technology and Sustainable Development, Vol. 11 Iss: 1, pp.53 - 65

**DOI** <http://dx.doi.org/10.1108/WJSTSD-09-2013-0039>

**Downloads:** The fulltext of this document has been downloaded 140 times since 2014

### Abstract:

#### Purpose

– The purpose of this paper is to map out the Indian nanotechnology innovation system. An attempt is made to identify the dominant actors, collaborative pattern and analyse the role of and interactions between the actors and institutions.

#### Design/methodology/approach

– A combination of frameworks such as national and international system of innovation is used to include all possible actors and institutions involved. A scientometric analysis is also carried out.

#### Findings

– Despite a series of government interventions discernible in various programmes since the 1980s, nanotechnology-based industries are yet to emerge as a dominant sector. The health sector has emerged as one of the major contributors in terms of nanotechnology applications. There are many other challenges of safety and standards, socioeconomic, ethical and environmental concerns. Academic R&D labs are active in technology transfer.

#### Research limitations/implications

– A scant literature is available for this sector in India and especially from the international innovation system framework to analyse the socioeconomic and risk governance issues.

#### Practical implications

– A scant literature is available for this sector in India and especially from the international innovation system framework to analyse the socioeconomic and risk governance issues.

#### Originality/value

– A scant literature is available for this sector in India and especially from the international innovation system framework to analyse the socioeconomic and risk governance issues.

**Keywords:** India, Nanotechnology, Innovation systems, International collaborations

[Factors influencing the adoption of internet banking: a case study of commercial banks in Mauritius](#)

[Organization structure theories and open innovation paradigm](#)

[Clean energies development in built environment](#)

[The identity crisis of sustainable development](#)

[See More](#)

### Share



### Further Information

[About the Journal](#)

[Sample Articles](#)

[Purchase Information](#)

[Editorial Team](#)

[Write for this journal](#)

**Important platform maintenance:** Emerald Insight will be undergoing essential maintenance on Tuesday 6th October 2015 from 07:00 GMT for up to 12 hrs.

[Home](#) | [Journals & Books](#) | [Case Studies](#) | [Author Services](#)

Resource areas: [Emerald Resources](#)



in: [This Journal](#)

[Search](#)

[Advanced Search](#)

[Home](#) > [Browse Journals & Books](#) > [World Journal of Science, Technology and Sustainable Development](#) > [Volume 11, Issue 1](#) > [Mapping the Indian nanotechnology innovation system](#)



## World Journal of Science, Technology and Sustainable Development

ISSN: 2042-5945

Online from: 2010

Subject Area: [Public Policy & Environmental Management](#)

[Current Issue](#) | [Available Issues](#) | [Most Cited](#) | [Most Read](#) | [ToC Alert](#) | [RSS](#) | [Add to favorites](#)

[◀ Previous Article](#)

[New multi-disciplinary approaches](#)

[Next Article ▶](#)



Vyberte jazyk

[Translator disclaimer](#)

## Mapping the Indian nanotechnology innovation system

### Article Options and Tools

View: [HTML](#) | [PDF](#)

[Most Read](#) | [Most Cited](#) | [Related](#)

The most popular articles from this title:

[Last Year](#) | [Last 7 Days](#)

[Corporate social responsibility and its link to financial performance : Application to Johnson & Johnson, a pharmaceutical company](#)

[Factors influencing the adoption of internet banking: a case study of commercial banks in Mauritius](#)

[Organization structure theories and open innovation paradigm](#)

[Clean energies development in built environment](#)

[The identity crisis of sustainable](#)

Přepnuli jste do režimu celé obrazovky. [Ukončit režim celé obrazovky \(F11\)](#)



# Mapping the Indian nanotechnology innovation system

## Article Options and Tools

View:



HTML



PDF

References (16)

[Add to Marked List](#)

[Download Citation](#)

[Track Citations](#)



[Reprints & Permissions](#)

Author(s): Amit Kumar (Centre for Studies in Science Policy, Jawaharlal Nehru University, New Delhi, India)  
Pranav N. Desai (Centre for Studies in Science Policy, Jawaharlal Nehru University, New Delhi)

Citation: Amit Kumar , Pranav N. Desai , (2014) "Mapping the Indian nanotechnology innovation system of Science, Technology and Sustainable Development, Vol. 11 Iss: 1, pp.53 - 65



Downloads: The fulltext of this document has been downloaded 140 times since 2014

Abstract:

#### **Purpose**

– The purpose of this paper is to map out the Indian nanotechnology innovation system. An attempt is made to identify the dominant actors, collaborative pattern and analyse the role of and interactions between the actors and institutions.

#### **Design/methodology/approach**

– A combination of frameworks such as national and international system of innovation is used to include all possible actors and institutions involved. A scientometric analysis is also carried out.

#### **Findings**

– Despite a series of government interventions discernible in various programmes since the 1980s, nanotechnology-based industries are yet to emerge as a dominant sector. The health sector has emerged as one of the major contributors in terms of nanotechnology applications. There are many other challenges of safety and standards, socioeconomic, ethical and environmental concerns. Academic R&D labs are active in technology transfer.

#### **Research limitations/implications**

– A scant literature is available for this sector in India and especially from the international innovation system framework to analyse the socioeconomic and risk governance issues.

#### **Practical implications**

– A scant literature is available for this sector in India and especially from the international innovation system framework to analyse the socioeconomic and risk governance issues.

#### **Originality/value**

– A scant literature is available for this sector in India and especially from the international innovation system framework to analyse the socioeconomic and risk governance issues.

Keywords: India, Nanotechnology, Innovation systems, International collaborations

Publisher: Emerald Group Publishing Limited

## Further Information

[About the Journal](#)

[Sample Articles](#)

[Purchase Information](#)

[Editorial Team](#)

[Write for this journal](#)



## Department of Health and Human Services

### Part 1. Overview Information

<b>Participating Organization(s)</b>	National Institutes of Health ( <a href="#">NIH</a> )
<b>Components of Participating Organizations</b>	National Institute of Biomedical Imaging and Bioengineering ( <a href="#">NIBIB</a> ) National Cancer Institute ( <a href="#">NCI</a> ) National Eye Institute ( <a href="#">NEI</a> ) National Human Genome Research Institute ( <a href="#">NHGRI</a> ) National Heart, Lung, and Blood Institute ( <a href="#">NHLBI</a> ) National Institute on Aging ( <a href="#">NIA</a> ) National Institute on Alcohol Abuse and Alcoholism ( <a href="#">NIAAA</a> ) National Institute of Allergy and Infectious Diseases ( <a href="#">NIAID</a> ) National Institute of Arthritis and Musculoskeletal and Skin Diseases ( <a href="#">NIAMS</a> ) Eunice Kennedy Shriver National Institute of Child Health and Human Development ( <a href="#">NICHD</a> ) National Institute on Drug Abuse ( <a href="#">NIDA</a> ) National Institute on Deafness and Other Communication Disorders ( <a href="#">NIDCD</a> ) National Institute on Dental and Craniofacial Research ( <a href="#">NIDCR</a> ) National Institute of Environmental Health Sciences ( <a href="#">NIEHS</a> ) National Institute of Neurological Disorders and Stroke ( <a href="#">NINDS</a> ) National Institute of Nursing Research ( <a href="#">NINR</a> )
<b>Funding Opportunity Title</b>	<b>Nanoscience and Nanotechnology in Biology and Medicine (R21)</b>
<b>Activity Code</b>	<a href="#">R21</a> Exploratory/Developmental Research Grant Award
<b>Announcement Type</b>	Reissue of <a href="#">PA-08-053</a>
<b>Related Notices</b>	None
<b>Funding Opportunity Announcement (FOA) Number</b>	<b>PA-11-149</b>
<b>Companion FOA</b>	<a href="#">PA-11-148</a> , <a href="#">R01</a> Research Project Grant
<b>Number of Applications</b>	See <a href="#">Section III. 3. Additional Information on Eligibility</a>
<b>Catalog of Federal Domestic Assistance (CFDA) Number(s)</b>	93.286, 93.113, 93.867, 93.837, 93.172, 93.866, 93.173, 93.121, 93.113, 93.853, 93.279, 93.273, 93.361, 93.865, 93.846  93.855, 93.856
<b>FOA Purpose</b>	This initiative, issued by the National Institutes of Health, encourages applications from institutions/organizations that apply nanoscience and nanotechnology approaches to address problems in biology and medicine. The purpose of this FOA is to provide support for cutting-edge nanoscience and nanotechnology research that will lead to biomedical breakthroughs and new investigations into the diagnosis, treatment and management of an array of

**Komplexnost, na klíč, s přidanou hodnotou apod.**

## **Ambivalence a současně symbióza:**

- end-user (koncový uživatel) - ?
- information broker (zprostředkovatel, prostředník) - ?
- end user x final user (koncový x konečný uživatel) - ? (Gartner, EIU aj.)

## Custom solutions

Our clients ask us to solve problems that are specific to them.

Whether it is deciding which Latin American country will provide the best operating environment for a logistics business, predicting which cities in China will emerge in the coming years to have the most favourable income levels and socio-demographics for a specific consumer product or assessing distribution channels in Africa for construction equipment, we can help.

### Country and city forecasting

Our team comprises experts on every country in the world. If you need to know how quickly the US will grow over the next five years or what residential construction will take place in Saudi Arabia, we can help. Or in Thailand, Algeria or Kazakhstan. But sometimes five years is not enough.

Many of our clients have investment horizons measured in decades. Our proprietary methodologies let us look ahead 30 years or more, using frameworks you can understand and rely on.

And if countries are too broad for your business, we forecast growth, spending, income and investment in cities from Dongguan to Dhaka.


[Contact us](#)

Our site uses cookies

By continuing to browse the site you are agreeing to our use of cookies. Review our [cookies information page](#) for more details.

[Close](#)

# Malé opakování: Rešeršní strategie, které kladou důraz rovněž na analytický výběr zdroje



## Databases

Select the database(s) you would like to search, then click **Continue**

Search a single database by clicking on its name. Databases with checkboxes can be cross-searched.

[Select all databases](#) / [Clear all databases](#)

☒ [ABI/INFORM Dateline](#) (ID 5921)

**Business, Economics: local and regional business publications**

Search a unique resource focusing on hard-to-find local and regional business news coverage of large corporations, privately held companies, local start-ups, executive profiles, marketing, finance, and industry news. Provides access to business information not typically found in national news sources. Contains news and analysis, information on local markets, and more gathered from major business tabloids, magazines, daily newspapers, wire services, and city, state, and regional business publications. [more info...](#)

Coverage: 1985-current | [View titles](#)

☒ [ABI/INFORM Global](#) (ID 3)

**Business, Finance, Economics: journals, company profiles, Wall Street Journal**

Most scholarly and comprehensive way to explore and understand business research topics. Search nearly 3000 worldwide business periodicals for in-depth coverage of business and economic conditions, management techniques, theory, and practice of business, advertising, marketing, economics, human resources, finance, taxation, computers, and more. Expanded international coverage. Fast access to information on 60,000+ companies with business and executive profiles. Now includes The Wall Street Journal. [more info...](#)

Coverage: 1971 - current | [View titles](#)

☒ [ABI/INFORM Trade & Industry](#) (ID 5820)

**Business, Economics: trade and industry periodicals**

Search more than 1200 business periodicals with a trade or industry focus. Provides users with the latest industry news, product and competitive information, marketing trends, and a wide variety of other topics. Contains publications on every major industry, including finance, insurance, transportation, construction, and many more. [more info...](#)

Coverage: 1971 - current | [View titles](#)

☒ [Academic Research Library](#) (ID 4614)

Search for coverage of a broad range of subjects including arts, business, children, education, general interest, health, humanities, international, law, military, multicultural, psychology, sciences, social sciences, and women's interests. [more info...](#)

Coverage: 1971 - present | [View titles](#)

☒ [Accounting & Tax](#)

Comprehensive coverage of accounting and tax topics appearing in key industry publications and newspapers. The quintessential accountant's database.

Coverage: varies | [View titles](#)

☒ [Accounting & Tax Newspapers](#) (ID 4023)

**Accounting, Taxation, Finance: newspapers**

Search newspapers for the latest accounting and tax news.

Coverage: 1971 - current | [View titles](#)

#### nearby: journals, magazines

Find complete, full-text information from covering numerous aspects of family health from sports injuries to women's health, from food and nutrition to midwifery, from eye care to dentistry.

Coverage: Varies | [View titles](#)

#### ☒ [ProQuest Health and Medical Complete](#) (ID 4795)

##### Health, Medicine: Journals, Magazines

Designed to serve a wide range of people who need health information -- from hospital administrators to medical professionals to consumers. The database provides coverage from leading health journals and essential medical journals in key medical specialties. [more info...](#)

Coverage: varies | [View titles](#)

#### ☒ [ProQuest Medical Library](#) (ID 2390)

Search a comprehensive database combining MEDLINE indexing with full images for more than 450 key medical titles. Offers coverage of all the major healthcare specialties, including nursing, pediatrics, neurology, pharmacology, cardiology, physical therapy, and others. [more info...](#)

Coverage: varies | [View titles](#)

#### ☒ [ProQuest Military Collection](#) (ID 6960)

Search a comprehensive collection of material on military subjects such as defense, aeronautics and space flight, civil engineering, political science, and more. [more info...](#)

Coverage: varies | [View titles](#)

#### ☒ [ProQuest Newspapers](#)

Search the full collection of newspapers.

Coverage: varies | [View titles](#)

#### ☒ [ProQuest Newsstand](#) (ID 1906)

Full text of 300+ U.S. and international news sources. Includes coverage of 150+ major U.S. and international newspapers such as The New York Times and the Times of London, plus hundreds of other news sources and news wires. [more info...](#)

Coverage: varies | [View titles](#)

#### ☒ [Advocate](#) (ID 13475)

Selectable newspaper subset. [more info...](#)

Coverage: varies | [View titles](#)

#### ☒ [Chicago Tribune](#) (ID 541)

Provides reporting and analysis of regional, national, and international news. [more info...](#)

Coverage: 1985-current | [View titles](#)

#### ☒ [Greenwich Time](#) (ID 13474)

Selectable newspaper subset.

Coverage: varies | [View titles](#)

## Medical Evidence Matters

### Medicine: Evidence-Based

A database designed to allow users to assess therapy options for known medical conditions by comparing outcomes from the peer-reviewed literature. [more info...](#)

Coverage: varies

### ☒ Nursing & Allied Health Source

Search full-text journals and dissertations in ProQuest Nursing & Allied Health Source alongside Systematic Reviews, Evidence Summaries, and Best Practice Information Sheets from the renowned Joanna Briggs Institute.

Coverage: varies | [View titles](#)

### ☒ ProQuest Nursing & Allied Health Source (ID 5441)

#### Nursing, Allied Health: Journals, Magazines, Dissertations

Find complete, full-text information from leading nursing, allied health, and related publications. Designed to meet the needs of researchers at health-care facilities as well as students enrolled in nursing and allied health programs at academic institutions. [more info...](#)

Coverage: varies | [View titles](#)

### ☒ Pharmaceutical News Index (ID 2)

Search the definitive database of pharmacological news, research, and regulatory information. Covers the most important specialized publications in the pharmaceutical, health care, biotechnology, and medical device industries. [more info...](#)

Coverage: varies | [View titles](#)

### ☒ ProQuest Asian Business and Reference (ID 2362)

#### Business, Finance, Economics: journals, magazines

Find the latest business and financial news from the Eastern Hemisphere. Covers Asian business and financial information from key international publications including Far Eastern Economic Review, Asiaweek, and many more. [more info...](#)

Coverage: 1971 - present | [View titles](#)

### ☒ ProQuest Biology Journals (ID 5442)

#### Science, Biology: Journals and magazines

Search full-text journals in the life sciences. [more info...](#)

Coverage: 1998 - current | [View titles](#)

### ☒ ProQuest Central (ID 25443)

ProQuest Central is the largest multidisciplinary database with over 12,665 titles, with over 9,745 titles in full-text. It serves as the central resource for researchers at all levels in all markets. Over 160 subjects areas are covered extensively in this product including business and economics, health and medical, news and world affairs, technology, social sciences and more.

Coverage: varies | [View titles](#)

### ☒ ProQuest Computing (ID 3194)

#### Science, Technology: Journals and magazines

Search top computing journals in full text for research on subjects such as database design, software development, web commerce, LANs, WANs, Intranets, and the Internet. [more info...](#)

Coverage: 1998 - current | [View titles](#)



Basic

Advanced

Topics

Publications

My Research  
0 marked items

Interface language:

English

Go

[Databases selected:](#) Multiple databases...

## Document View

[« Back to Results](#)[< Previous](#) Document 2 of 214 [Next >](#)[Print](#) | [Email](#) | [Copy link](#) | [Cite this](#) | [Mark Document](#)Translate document from: [Select language](#)

## Life Science Intelligence; Valuations and Exit Strategies for Medtech Companies in the New Economy Analyzed in Online Industry Presentation by Medical Capital Advisors Chairman & CEO Christopher J.P. Velis

*Anonymous.* [Medical Devices & Surgical Technology Week](#). Atlanta: [Feb 14, 2010](#). pg. 572

## Abstract (Summary)

2010 FEB 14 - (<http://www.newsrx.com>> NewsRx.com) -- Life Science Intelligence (LSI) announced that medical technology investment banking veteran Christopher J.P. Velis of Medical Capital Advisors would kick off their Emerging Medical Technologies Spotlight - an online event showcasing 40 emerging medical device companies - with an industry presentation titled "Valuations and Exit Strategies for Medtech Companies in the New Economy: The 10 Things Every Startup, Investor, and Dealmaker Needs to Know." Mr. Velis' one-hour industry presentation, which will be released in an interactive webinar format, will provide startup CEOs, business development executives, and venture capitalists with a practical and realistic picture of what to expect in terms of valuations and exits in 2010. Mr. Velis' discussion will be followed by detailed business presentations from the CEOs of 40 privately-held emerging medical device companies selected by event host Life Science Intelligence. Each of the 40 presenting companies is seeking strategic partners and/or raising capital. Register here to access the event (see also <http://www.newsrx.com/library/topics/Life-Science-Intelligence.html>> Life Science Intelligence).

[» Jump to indexing \(document details\)](#)

## Full Text (567 words)

*(c)Copyright 2010, Medical Devices & Surgical Technology Week via NewsRx.com*

2010 FEB 14 - (<http://www.newsrx.com>> NewsRx.com) -- Life Science Intelligence (LSI) announced that medical technology investment banking veteran Christopher J.P. Velis of Medical Capital Advisors would kick off their Emerging Medical Technologies Spotlight - an online event showcasing 40 emerging medical device companies - with an industry presentation titled "Valuations and Exit Strategies for Medtech Companies in the New Economy: The 10 Things Every Startup, Investor, and Dealmaker Needs to Know." Mr. Velis' one-hour industry presentation, which will be released in an interactive webinar format, will provide startup CEOs, business development executives, and venture capitalists with a practical and realistic picture of what to expect in terms of valuations and exits in 2010. Mr. Velis' discussion will be followed by detailed business presentations from the CEOs of 40 privately-held emerging medical device companies selected by event host Life Science Intelligence. Each of the 40 presenting companies is seeking strategic partners and/or raising capital. Register here to access the event (see also <http://www.newsrx.com/library/topics/Life-Science-Intelligence.html>> Life Science Intelligence).

Attendees receive online access to Mr. Velis' presentation and 10-15 minute CEO presentations (audio and slides); a notebook of executive summaries; and detailed information, such as: development stage, competitive landscape and positioning, technological advantage, target markets, sales forecasts, financial and fund raising status, management team, IP position, exit strategy, and contact details.

Companies on the program thus far include: Aardvark Medical, Advanced Ophthalmic Pharma, Angel Medical Systems, ArtVentive Medical, Bakhtar Medical Imaging, Biomedix, Branching Tree, CardioMag, Cardious, Epinex Diagnostics, Heart Test Labs, Izun Pharmaceuticals, Lerner Medical Devices, LightIntegra, MEDTRONS, Mobius Therapeutics, Near Infrared Imaging, NuOrtho Surgical, Optical Imaging, Pico-Tesla Magnetic Therapies, PolyRemedy, Qscope, Renova Orthopedics, Sara Medical Devices, Seguro Surgical,

## Other available formats:

[Abstract](#)

## Find more documents like this:

## Author(s):

☐ Anonymous

## Document types:

☐ Expanded Reporting

## Publication title:

☐ Medical Devices & Surgical Technology Week

Search

Clear



**DataStar Web - Quick Search (MOJO) - Microsoft Internet Explorer**

Soubor Úpravy Zobrazit Přejít Oblíbené nápověda

Zpět Vpřed Stop Obnovit Domů Hledat Oblíbené Tisk Písmo Pošta

Adresa  Odkazy

---



## Euromonitor Journals (MOJO)

Search tips:

- For a list of words beginning with "employ" type **employ?**
- To search for all words beginning with "employ" type **employ\$**
- OR two terms together like this: **solar energy, solar power**
- Remove punctuation (e.g.) **Knight Ridder Information** not "Knight-Ridder Information"

---

Enter your search term(s) and choose the part of the document to be searched

**AND**

☒ Save Search

From date:  (YYMMDD)

Hotovo

**DataStar Web - Titles (MOJO) - Microsoft Internet Explorer**

Soubor Úpravy Zobrazit Přejít Oblíbené Nápověda

Zpět Vpřed Stop Obnovit Domů Hledat Oblíbené Tisk Písmo Pošta

Adresa <http://dsweb.krinfo.ch/2010a1fb/wBSEARCHBUTTON/1001/e06c1fb7/> Odkazy

**DATASTAR WEB** KR DM

Logout Back to Subjects Databases New Search Options Costs Help

## Euromonitor Journals (MOJO)

Your search for **BEER\$.TL AND GERMAN\$.TL** resulted in **1** document.

Documents 1 to 1 of 1:

☒ 1 [table of contents](#)  
*May 1997 (9705). THE GERMAN MARKET FOR BEER.*


The documents will be shown in the following print-format:


☒ Table-of-Contents ☐ Free ☐ Short ☐ Medium ☐ Long ☐ Bibliographic

The documents will be shown in the following output-format:

☒ HTML ☐ Tagged

**Attention:**  
FRA Redistribution is not allowed for the following database(s): **MOJO**







## **Identifikace jádra informačních zdrojů, případové úlohy a jejich komentáře ...**

## STN on the web

- About
- First Time User
- Free Search Preview
- Customer Support
- Get Structure Plug-in
- Get Sequence Plug-in
- Standard Login
- Academic Login
- Secure Session
- STN Links
- Feedback

Your search preview results are shown below.

The selected field of interest is "MEDICINE" (Medicine and Medical Science Cluster)  
The selected databases are: MEDICINE

Search Terms: hepsera

### Answers Databases

22	NLDB
18	EMBASE
16	PHIN
8	TOXCENTER
7	ADISNEWS
7	IPA
7	PHARMAML
6	DRUGNL
4	ADISCTI
3	BIOTECHNO
2	ADISINSIGHT
2	DRUGLAUNCH
2	DRUGMONOG2
2	SCISEARCH
1	MEDLINE
1	PASCAL



# Bibliometrické nástroje analytické a kreativní hledání souvislostí: některé mizí, jiné přichází

- ◆ STN Index
- ◆ Dialindex ☹ -- zrušen
- ◆ Dialog Company Name Finder
- ◆ Dialog Product Name Finder
- ◆ Dialog Journal Name Finder ... vše  
zrušeno

Ale ...



## Analysis and visualization software for information professionals

### Features and Benefits

- Analyze the patent landscape to determine emerging trends and leaders.
- Stay ahead of your competitors.
- Support strategic business planning.
- Integrate content from multiple databases.
- Quickly view interactive relationships among data and charts.

STN® AnaVist™ was designed for use with STN Express® or STN® on the Web<sup>SM</sup> to search indexed, full-text patent databases (2AnaVist):

- [CAplus<sup>SM</sup>](#) - Chemical Abstracts Plus
- [EPFULL](#) - European Patents Fulltext
- [PCTFULL](#) - WIPO/PCT Patents Full Text
- [USPAT2](#) - U.S. Patents Latest Publications
- [USPATFULL](#) - U.S. Patents Original Publications
- [WPINDEX](#) - (WPIDS and WPIX subscribers will see the WPINDEX content)

### New to STN AnaVist?

- [Take a Test Drive of STN AnaVist \(PDF\)](#)
- [STN AnaVist Test Projects Request Form \(PDF\)](#)
- [STN AnaVist License Agreement \(PDF\)](#)
- [STN AnaVist CD-ROM Order Form \(PDF\)](#)

### STN Information

- [Overview](#)
- [Content](#)
- [New STN](#)
- [Global Value Pricing](#)
- [Customer Support & Training](#)
- [STN News](#)

### STN News - What's New on STN

[September, 2015](#) | PatentPak - A Time Saving Solution for IP Professionals - Is Coming to STN in Early 2016!

[July/August, 2015](#) | Latest New STN Release Features Eight New Databases Including MARPAT from CAS for Markush Structure Searching

[June, 2015](#) | CAS REGISTRY – 50 Years Strong, 100 Million Substances Driving Your Research

[See More STN News >>](#)

[View](#) or [sign-up](#) for STN News e-Newsletter



# Thomson Data Analyzer

IP analysis made easy

## Description:

Thomson Data Analyzer™ desktop software offers a powerful interface for managing and extracting business-critical insights from patent and scientific data within in-house or commercial databases.

With its advanced analysis technology, Thomson Data Analyzer empowers users to analyze patent data and scientific literature from any structured database directly on their desktop. It allows you to cut through masses of data to give you clear and definitive insights - at a glance.

Thomson Data Analyzer provides an easy way to analyze trends, profile competitors, avoid or uncover patent and copyright infringement, and identify strategic development opportunities in information.

[Contact Sales >](#)


---

[Features](#)[Benefits](#)[Already a Customer](#)


---

Searching Session 2016

# Příklad: ProQuest



# Příklad: I2 IBM





```
javascript:window.close()
```



# **Případové úlohy a komentáře ...**





Home



Subscribers



Services



About Us

Conference Reports

Links



REQUEST A DEMO

## Pharmaceutical R&D Pipeline News

### Start Making Sense - Exon Skipping & Nonsense Suppression

A joint revolution in the treatment of genetic disease?

Twenty-two years ago, the largest gene found in nature was isolated, and a year later it was sequenced. This 2.4Mb leviathan encoded no mere housekeeping protein – its 3685-amino-acid product, a rod-shaped human muscle protein now known as dystrophin, is of profound significance to families affected by the various forms of muscular dystrophy, a disease which occurs in 1 in 3500 newborn males.

However, 22 years on, the slow progress of gene therapies to market has been profoundly disappointing in all sectors, not only for muscular dystrophy or other genetic diseases – as yet, following a quarter of a century of frenetic R&D activity, there are still only two gene therapies launched worldwide, and both of these are for cancer...



[read full article >>](#)

### Mergers, Acquisitions & Joint Ventures

Onyx Pharmaceuticals has acquired Proteolix.

ACE Biosciences has become a subsidiary of Zymenex.

GPC Biotech has merged into Agennix.

### New Drug Targets

Newly identified drug protein targets.

» [endo/exonuclease \(5'-3'\), endonuclease G-like](#)

### Newsletter Signup

Email:

Company:

### Pharma R&D Pipeline Intelligence

Our pharmaceutical research commentary & drug development news are derived from

Pharmaprojects' R&D pipeline intelligence data. Pharmaprojects' research & development pipeline intelligence is your answer to an increasingly competitive pharmaceutical market...

[..more about us](#)

### Company Analysis

Drug development strategies of the key players in Pharmaceutical R&D..

### Therapy Analysis

A therapeutic insight into R&D trends in the pharmaceutical industry..

What can you do with Pharmaprojects' R&D pipeline intelligence?

Watch our presentation or try Pharmaprojects to find out..

## Pharmaprojects\*

\*Subscriber access only

### Description

Pharmaprojects provides up-to-date intelligence on new pharmaceutical products under development, from early pharmacological studies to launch. It covers pharmaceuticals as well as biotechnological products, new formulations and combinations under development anywhere in the world, from pre-clinical through all phases of clinical development, pre-registration, approval and launch. It also includes information on discontinued drugs.

### Date Coverage

1981 to the present

### Geographic Coverage

International

### Publisher

Pharmaprojects is provided by Informa UK Ltd. Questions concerning file content should be directed to:

Informa UK Ltd.  
Pharmaprojects Helpdesk  
69-77 Paul Street  
London, EC2A 4LQ  
United Kingdom



### Subject Coverage

Pharmaprojects primarily addresses the information needs of the pharmaceutical industry and closely related fields, but is also of interest to those involved in the evaluation of pharmaceutical company performance. Most documents contain the product name, synonyms, originating company and development status, licensees and development status, CAS® Registry Number, molecular formula, pharmacology and descriptive text.

### Update Frequency

Weekly

### Document Types

Reports of drug development

**Telephone:** +44 (0) 20 7017 6868  
**Fax:** +44 (0) 20 7017 6905  
**E-Mail:** [pharmaprojects.help@informa.com](mailto:pharmaprojects.help@informa.com)



#	Search History	Results	Display
-	-	-	-

 [Saved Searches](#)

Enter **Keyword** or phrase:

 Perform Search

**Limit to:**

☐ Latest Update ☐ Image ☐ Active Program

Copyright (c) 2000-2003 [Ovid Technologies, Inc.](#)

Version: rel6.1.0, SourceID 1.7672.1.63

Search  
Fields

Combine




Limit



Basic




Logoff

#	Search History	Results	Display
1	hepsera.mp. [mp=descriptor words, drug word, general comments, commercial summary]	1	

 Saved Searches Save Search History Delete SearchesEnter **Keyword** or phrase:**Limit to:**☐ Latest Update ☐ Image ☐ Active ProgramResults of your search: **hepsera.mp. [mp=descriptor words, drug word, summary]**Citation displayed: **1 of 1**

Results of your search: **hepsara.mp. [mp=descriptor words, drug word, general comments, commercial summary]**

Citation displayed: **1** of **1**

Go to Record:  

[Citation Manager](#) • [Help](#) • [Logoff](#)

[Customize Display](#) [Reset Display](#)

☐ 1. **Accession Number:** 2005664

**Drug Name:** adefovir dipivoxil (BAN)

[Complete Reference](#) • [Image File \(GIF\)](#)

### Citation Manager: Display, Print, Save, or Email Citations

Citations	Fields	Citation Format	Action
<input checked="" type="radio"/> Selected Citations <input type="radio"/> All in this set (1-1)  and/or Range: <input type="text"/>	<input type="radio"/> Citation (Title, Author, Source) <input checked="" type="radio"/> Citation + Abstract <input type="radio"/> Citation + Abstract + Subject Headings <input type="radio"/> Complete Reference <input type="button" value="Select Fields"/>	<input checked="" type="radio"/> Ovid <input type="radio"/> BRS/Tagged <input type="radio"/> Reprint/Medlars <input type="radio"/> Brief (Titles) Display <input type="radio"/> Direct Export  <input type="checkbox"/> Include Search History	<input type="button" value="Display"/> <input type="button" value="Print Preview"/> <input type="button" value="Save"/>
<h3>Sort Keys</h3>			
Primary:	<input type="text" value="-"/>	<input type="button" value="v"/>	Ascending <input type="button" value="v"/>
Secondary:	<input type="text" value="-"/>	<input type="button" value="v"/>	Ascending <input type="button" value="v"/>

## □ Citation 1.

Link to... [Image File \(GIF\)](#)

Copyright 2003 IMS Health Incorporated or its affiliates. All rights reserved.

### Accession Number

2005664

### Drug Name

adefovir dipivoxil (BAN)

### Synonyms

GS 840, **HEPSERA**, RESPUR, PREVEON

### Highest Phase

Marketed

### Active Program

Yes

### Chemical Name

2,2-dimethylpropanoic acid [[[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]phosphinylidene]bis  
(oxymethylene) ester

### CAS Registry Numbers

142340-99-6 (adefovir dipivoxil), 220351-05-3 (cpd with succinic acid (1:1)), 220351-03-1 (fumarate (1:1)), 220351-10-0 (maleate (1:1)), 220351-14-4 (cpd with L-ascorbic acid (1:1)), 220351-22-4 (cpd with methanol (1:1)), 220350-43-6 (dihydrate), 220350-98-1 (monocamsilate), 220350-82-3 (monomesilate), 220350-60-7 (monohydrobromide), 220350-68-5 (monohydrochloride), 220350-82-3 (monoesilate), 220350-94-7 (mono-1-naphthalenesulfonate), 220350-89-0 (mononapsilate), 220350-73-2 (mononitrate), 220351-17-7 (mononicotinate), 220350-52-7 (sulfate (2:1))

## **General Comments**

20030609 pc Launch. Gilead Sciences' reverse transcriptase inhibitor, adefovir dipivoxil (**HEPSERA**), has been launched in Germany for the treatment of chronic hepatitis B virus infection.

## **Company Information**

Originator: Bristol-Myers Squibb, USA

Licensee: Gilead Sciences, USA

Licensee: GlaxoSmithKline, UK

## **Indication**

[cytomegalic inclusion disease](#), [hepatitis](#), [viral infection](#)

## **EphMRA Code**

J5B Antivirals, Excluding Anti-HIV Products

## **Latest Change**

20030609

## **Commercial Summary**

Gilead Sciences is developing a mononucleotide analogue, adefovir dipivoxil, an oral, once-daily prodrug of adefovir, for the treatment of viral infection. Applications for marketing approval of the agent in the treatment of chronic hepatitis B virus (HBV) infection, in treatment-naïve and treatment-experienced patients, have been made in the USA and Europe (Gilead Sciences, MAR 2002). The US FDA approved the agent as a treatment for HBV infection and a launch has subsequently taken place in this market (Gilead Sciences, SEP 2002). The agent has also been approved in Europe as a treatment for HBV infection, and launches have taken place in the UK (Pharmaceutical Journal, APR 2003) and Germany (IMS, APR 2003). Filings have been submitted to regulatory authorities in Australia, Canada and Switzerland (Gilead Sciences, MAR 2003). An early access program was initiated in the USA for use of adefovir dipivoxil 10 mg in the treatment of patients with chronic HBV infection resistant to lamivudine and the program has been extended to Canada, Australia, and most European countries



## **Licensing Status**

Unavailable for Licensing: Japan

Unavailable for Licensing: Taiwan

Unavailable for Licensing: South Korea

Unavailable for Licensing: China

## **Patent Assignee**

Bristol-Myers Squibb

## **Patent Summary**

Product: EP 481214 B 1998, priority US 583906 1990, designating 14 states. Equivalents identified in five countries.

## **Development Status**

Marketed: USA, hepatitis

Phase III: USA, cytomegalic inclusion disease

Marketed: UK, hepatitis

Marketed: Germany, hepatitis

Registered: Europe, hepatitis

Pre-registration: Switzerland, hepatitis

Pre-registration: Canada, hepatitis

Pre-registration: Australia, hepatitis

Phase III: South-East Asia, hepatitis

Phase I: China, hepatitis

## **Substance Origin**

chemical synthesis



## **Mechanism of Action**

reverse transcriptase inhibitor, nucleotide analogue

## **Clinical Overview**

In vitro, adefovir dipivoxil is effective against most drug-resistant HIV strains including with a Q151 mutation, and shows synergy with nucleoside analogues and proteinase inhibitors (Gilead Sciences, MAY 1997). Oral adefovir dipivoxil is rapidly converted to adefovir. Adefovir dipivoxil was associated with reduced p24 antigenemia and transient increases in CD4 counts in some patients infected with HIV. A phase I/II trial showed that once daily adefovir dipivoxil was safe and well tolerated at three different dose levels and caused a drug related decrease in p24 antigen levels in HIV-infected patients. Side effects included mild to moderate gastrointestinal symptoms. Oral bioavailability for adefovir dipivoxil was 40%. A phase I/II, trial showed adefovir dipivoxil at doses of 125 or 250 mg/day produced sustained increases in CD4 cell counts of 46 and 15 cells/mm<sup>3</sup> from baseline, respectively, versus -41 cells/mm<sup>3</sup> for placebo following 6 week treatment. Viral load, as measured by HIV RNA, was decreased by median -0.5 log copies/mL and -0.4 log copies/mL at the 125 and 250 mg doses, respectively. Detectable CMV levels were reduced in comparison with placebo in a subset of patients. In study 411 involving treatment-naïve HIV-positive patients receiving adefovir dipivoxil, indinavir and one or two reverse transcriptase inhibitors (zidovudine, lamivudine or stavudine), or standard triple therapy (zidovudine, lamivudine and indinavir), 80% of patients receiving regimens with or without adefovir dipivoxil had undetectable levels of HIV RNA at 20 week. Triple drug regimens containing adefovir dipivoxil increased CD4 cells by 92 cells/mm<sup>3</sup>, compared with an increase of 66 cells/mm<sup>3</sup> with the standard triple therapy. Elevations in liver transaminase and creatine kinase occurred in 8% and 3% of the adefovir dipivoxil group and 5% and 5% of the standard group, respectively (Gilead Sciences, APR 1998). In study 408, 442 HIV-positive patients were randomized to receive 120 mg adefovir dipivoxil (219 patients) or placebo (223 patients) once daily in addition to current antiretroviral therapy. In


## **Drug Development History**

200304: Marketed, UK, Germany (HBV).  
200303: Registered, Europe (HBV).  
200211: Recommended, Europe (HBV).  
200209: Registered and Marketed, USA (HBV).  
200208: Recommended, USA (HBV).  
200204: Licensing agreement between Gilead Sciences and GlaxoSmithKline.  
200203: Pre-registration, USA, Europe (HBV).  
200101: Phase I, China (HBV).  
199912: Discontinued (HIV).  
199910: Pre-registration, Europe (HIV). Approval not recommended, USA (HIV)  
199904: Phase III, USA, Europe, Canada, Australia, Asia (HBV).  
199903: Expanded access program expanded.  
199901: Pre-registration, USA.  
199811: Fast track designation.  
199703: Phase II, USA, UK, Australia, Canada (HBV).  
199701: Phase III, USA (HIV, CMV).  
199606: Phase II/III, USA (HIV).  
199504: Phase I/II, UK, (HBV).  
199408: Phase I/II, USA (HIV).  
199404: Phase I, USA.  
199401: Preclinical, USA.  
199009: Priority product patent application filed, USA.

## **Update Code**

20030605

# Děkuji Vám za pozornost.



Spojení: např. <http://www.linkedin.com/in/papik>